The global therapeutic vaccines market size reached US$ 25.63 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 49.89 Billion by 2027, exhibiting a growth rate (CAGR) of 11.40% during 2022-2027.

Therapeutic vaccines are a range of biological medications designed to stimulate or trigger the adaptive immune system to prevent disease-causing organisms and infections. They can be modified based on various applications and needs for treating different disorders, including cancer, human immunodeficiency virus (HIV) infections, and Alzheimer’s. Therapeutic vaccines aid in creating antibodies for protecting the body against pathogens, recognizing viruses or cancerous cells, reducing the viral set point in infected patients, and providing better clinical outcomes. Along with this, they are cost-effective, easy to use, and can treat late-stage diseases; thus, it is extensively used in clinical laboratories, hospitals, and vaccination centers for immunization. Currently, they are available in autoimmune, cancer, infectious and neurological disease vaccination types.

Therapeutic Vaccines Market Trends:
The increasing prevalence of various chronic ailments and the growing need for effective biologic medications for specific and targeted responses are primarily driving the therapeutic vaccines market growth. In line with this, the implementation of numerous government initiatives promoting compulsory immunization of individuals during the COVID-19 pandemic and the ongoing funding in biopharmaceutical companies to develop viral recombinants are acting as another growth-inducing factors. Additionally, the extensive utilization of morphogenesis gene therapy with exosome-mediated delivery technology for the advent of patient-specific vaccines to deal with varying cancer types is impelling the market growth. This is further supported by the escalating uptake of genetic engineering, the availability of quick deployment vaccines, and the introduction of faster drug development solutions to improve medicine designs. Apart from this, rapid enhancements in the healthcare sector, fueling consumer awareness regarding the accessibility to several therapeutic drugs, and ongoing research and development (R&D) activities to enhance product effectiveness are creating a positive outlook for the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global therapeutic vaccines market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, disease type, technology and distribution channel.

Breakup by Type:

Antigen Vaccines
Dendritic Cell Vaccine
DNA Vaccine
Tumor Cell Vaccines

Breakup by Disease Type:

Autoimmune Disease Vaccines
Addiction Vaccine
Neurological Disease Vaccine
Infectious Disease Vaccine
Others

Breakup by Technology:

Autologous Vaccines
Allogeneic Vaccine

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agenus Inc., Argos Therapeutics Inc., Bavarian Nordic A/S, Cel-Sci Corporation, CSL Limited, Emergent Biosolutions Inc., GSK plc, Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.

Key questions answered in this report:
How has the global therapeutic vaccines market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global therapeutic vaccines market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the disease type?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global therapeutic vaccines market and who are the key players?
What is the degree of competition in the industry?